Sartorius (SRT) AI Stock Analysis

• Market Cap: €11.85B
• Dividend Yield: 0.49%
• Average Volume (3M): 8.48K
• Price to Earnings (P/E): 103.1
• Beta (1Y): 1.55
• Revenue Growth: 3.80%
• EPS Growth: 33.31%
• Country: DE
• Employees: 13,573
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 1.22
• Shares Outstanding: 37,440,000
• 10 Day Avg. Volume: 9,526
• 30 Day Avg. Volume: 8,477
• PEG Ratio: 16.87
• Price to Book (P/B): 5.40
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 18.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €255.00
• Price Target Upside: 70.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 60 Neutral
• Price Target: €165.00 ▲(10.29%Upside)

Sartorius's overall score is influenced most by its mixed financial performance, with strong cash flow but high leverage and profitability pressures. Technical analysis indicates a bearish trend, while valuation suggests overvaluation. The earnings call adds a cautiously optimistic view with strong growth tempered by industry challenges.

Sartorius Business Overview & Revenue Model

Company Description

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

How the Company Makes Money

Sartorius generates revenue primarily through the sale of its bioprocess solutions and laboratory products. The Bioprocess Solutions division, which contributes the majority of the company's revenue, focuses on providing products and services that facilitate the production of biopharmaceuticals, such as cell culture media, single-use technologies, and downstream processing equipment. The Lab Products & Services division generates income by supplying laboratory instruments and consumables used in research and quality assurance processes. Sartorius also benefits from long-term partnerships and collaborations with biotechnology companies, pharmaceutical manufacturers, and research institutions, which enhance its market reach and drive sales. Additionally, the company invests in innovation to expand its product portfolio and meet the evolving needs of its customers, thereby supporting sustained revenue growth.

Sartorius Financial Statement Overview

Summary

Sartorius demonstrates mixed financial performance with strong cash flow generation and operational efficiency. However, profitability pressures and high leverage pose potential risks.

Income Statement

Sartorius shows moderate revenue growth with a slight increase in TTM (Trailing-Twelve-Months) revenue compared to the previous annual period. However, the gross profit margin and net profit margin have weakened over the periods, indicating pressure on cost management and profitability. The EBIT and EBITDA margins suggest operational efficiency, but the declining net income is a concern.

Balance Sheet

The company's balance sheet reflects a stable financial structure with reasonable equity levels relative to assets. However, the debt-to-equity ratio is elevated, signaling potential leverage risks. Despite this, the return on equity remains positive, indicating effective use of shareholder funds.

Cash Flow

Sartorius exhibits strong cash flow generation capabilities, with consistent operating cash flow and positive free cash flow. The free cash flow growth is encouraging, though capital expenditure levels have been high. The operating cash flow to net income ratio indicates solid cash conversion efficiency.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.38B	3.40B	4.17B	3.45B	2.34B
Gross Profit	1.52B	1.57B	2.20B	1.84B	1.21B
EBITDA	786.80M	873.10M	1.54B	945.12M	662.13M
Net Income	84.00M	205.20M	913.10M	426.98M	321.47M
Balance Sheet
Total Assets	10.10B	9.76B	6.98B	5.70B	4.70B
Cash, Cash Equivalents and Short-Term Investments	828.70M	394.20M	196.80M	360.99M	217.65M
Total Debt	4.56B	5.31B	2.54B	2.08B	2.09B
Total Liabilities	6.21B	7.00B	4.32B	3.98B	3.30B
Stockholders Equity	2.76B	2.07B	1.99B	1.26B	1.05B
Cash Flow
Free Cash Flow	566.30M	293.90M	211.60M	458.65M	271.27M
Operating Cash Flow	976.20M	853.60M	734.20M	865.81M	511.52M
Investing Cash Flow	-425.80M	-2.82B	-1.13B	-569.61M	-1.27B
Financing Cash Flow	-128.30M	2.17B	209.90M	-165.18M	907.47M

Sartorius Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 149.60
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Negative. The current price of 149.6 is below the 20-day moving average (MA) of 166.51, below the 50-day MA of 170.02, and below the 200-day MA of 180.94, indicating a bearish trend. The MACD of -5.26 indicates Positive momentum. The RSI at 29.37 is Positive, neither overbought nor oversold. The STOCH value of 25.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SRT.

Sartorius Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	65 Neutral	¥352.42B	10.85	-2.99%	2.46%	11.67%	-10.31%
SRT	60 Neutral	€11.85B	103.06	3.88%	0.49%	3.80%	33.31%
0DHC	―	€4.14B	26.36	7.48%	1.16%	―	―
0H9X	―	€12.70B	20.54	4.37%	3.21%	―	―
0OO9	―	€23.41B	56.03	6.28%	2.39%	―	―
0O14	―	€47.96B	17.02	9.74%	1.90%	―	―
SEMHF	―	$60.06B	25.53	11.75%	1.77%	―	―